|
1
|
Genetic and Rare Diseases Information
Center (GARD), supported by ORDR-NCATS and NHGRI. http://www.diseaseinfosearch.org/result/5489
|
|
2
|
Harrison DJ, Geller DS, Gill JD, Lewis VO
and Gorlick R: Current and future therapeutic approaches for
osteosarcoma. Expert Rev Anticancer Ther. 18:39–50. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huang KL, Chen CF, Wu PK, Chen PC, Chen
WM, Liu CL and Chen TH: Clinical outcomes and prognostic factors of
Ewing sarcoma: A clinical analysis of 12 patients in Taiwan. J Chin
Med Assoc. 75:16–20. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ren L, Mendoza A, Zhu J, Briggs JW, Halsey
C, Hong ES, Burkett SS, Morrow J, Lizardo MM, Osborne T, et al:
Characterization of the metastatic phenotype of a panel of
established osteosarcoma cells. Oncotarget. 6:29469–29481. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Janeway KA and Grier HE: Sequelae of
osteosarcoma medical therapy: A review of rare acute toxicities and
late effects. Lancet Oncol. 11:670–678. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bernthal NM, Federman N, Eilber FR, Nelson
SD, Eckardt JJ, Eilber FC and Tap WD: Long-term results (>25
years) of a randomized, prospective clinical trial evaluating
chemotherapy in patients with high-grade, operable osteosarcoma.
Cancer. 118:5888–5893. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friedman MA and Carter SK: The therapy of
osteogenic sarcoma: Current status and thoughts for the future. J
Surg Oncol. 4:482–510. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marina N, Gebhardt M, Teot and Gorlick R:
Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bacci G, Mercuri M, Briccoli A, Ferrari S,
Bertoni F, Donati D, Monti C, Zanoni A, Forni C and Manfrini M:
Osteogenic sarcoma of the extremity with detectable lung metastases
at presentation. Results of treatment of 23 patients with
chemotherapy followed by simultaneous resection of primary and
metastatic lesions. Cancer. 79:245–254. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Navid F, Willert JR, McCarvile MB, Furman
W, Watkins A, Roberts W and Daw NC: Combination of gemcitabine and
docetaxel in the treatment of children and young adults with
refractory bone sarcoma. Cancer. 113:419–425. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Berger M, Grignani G, Ferrari S, Biasin E,
del Prever Brach A, Aliberti S, Saglio F, Aglietta M and Fagioli F:
Phase 2 trial of two courses of cyclophosphamide and etoposide for
relapsed high-risk osteosarcoma patients. Cancer. 115:2980–2987.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saylors RL III, Stine KC, Sullivan J,
Kepner JL, Wall DA, Bernstein ML, Harris MB, Hayashi R and Vietti
TJ; Pediatric Oncology Group, : Cyclophosphamide plus topotecan in
children with recurrent or refractory solid tumors: A pediatric
oncology group phase II study. J Clin oncol. 19:3463–3469. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maki RG, Wathen JK, Patel SR, Priebat DA,
Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D,
et al: Randomized phase II study of gemcitabine and docetaxel
compared with gemcitabine alone in patients with metastatic soft
tissue sarcoma: Results of sarcoma alliance for research through
collaboration study 002 [corrected]. J Clin Oncol. 25:2755–2763.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miser JS, Kinsella TJ, Triche TJ, Tsokos
M, Jarosinski P, Forquer R, Wesley R and Magrath I: Ifosfomide with
mesna uroprotection and etoposide: An effective regimen in the
treatment of recurrent sarcomas and other tumors of children and
young adults. J Clin Oncol. 5:1191–1198. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goorin AM, Harris MB, Bernstein M,
Ferguson W, Devidas M, Siegal GP, Gebhardt MC, Schwartz CL, Link M
and Grier HE: Phase II/III trial of etoposide and high-dose
ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric
oncology group trial. J Clin Oncol. 20:426–433. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Van Winkle P, Angiolillo A, Krailo M,
Cheung YK, Anderson B, Davenport V, Reaman G and Cairo MS:
Ifosfamide, carboplatin, and etoposide (ICE) reinduction
chemotherapy in a large cohort of children and adolescents with
recurrent/refractory sarcoma: The children's cancer group (CCG)
experience. Pediatr Blood Cancer. 44:338–347. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Le Deley MC, Guinebretière JM, Gentet JC,
Pacquement H, Pichon F, Marec-Bérard P, Entz-Werlé N, Schmitt C,
Brugières L, Vanel D, et al: SFOP OS94: A randomized trial
comparing preoperative high-dose methotrexate plus doxorubicin to
high-dose methotrexate plus etoposide and ifosfamide in
osteosarcoma patients. Eur J Cancer. 43:752–761. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Anderson PM, Subbiah V and Rohren E:
Bone-seeking radiopharmaceuticals as targeted agents of
osteosarcoma: Samarium-153-EDTMP and radium-223. Adv Exp Med Boil.
804:291–304. 2014. View Article : Google Scholar
|
|
19
|
Subbiah V, Rohren E, Huh WW, Kappadath CS
and Aderson PM: Phase 1 dose escalation trial of intravenous radium
223 dichloride alpha-particle therapy in osteosarcoma. J Clin
Oncol. 32 15-Suppl:Abstract TPS 10600. 2014.
|
|
20
|
Grignani G, Palmerini E, Ferraresi V,
D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y,
Sangiolo D, Marchesi E, et al: Sorafenib and everolimus for
patients with unresectable high-grade osteosarcoma progression
after standard treatment: A non-radomised phase 2 clinical trial.
Lancet Oncol. 16:90–107. 2015. View Article : Google Scholar
|
|
21
|
Sun L, Li Y, Li H, Zhang J, Li B and Ye Z:
Analysis of chemotherapy dosage and dosage intensity and survival
outcomes of high-grade osteosarcoma patients younger than 40 years.
Clin Ther. 36:567–578. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jaffe N: Recent advances in the
chemotherapy of metastatic osteogenic sarcoma. Cancer.
30:1627–1631. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rosen G, Marcove RC, Caparros B, Nirenberg
A, Kosloff C and Huvos AG: Primary osteogenic sarcoma: The
rationale for preoperative chemotherapy and delayed surgery.
Cancer. 43:2163–2177. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rosen G and Nirenberg A: Neoadjuvant
chemotherapy for osteogenic sarcoma: A five year follow-up (T-10)
and preliminary report of new studies (T-12). Prog Clin Biol Res.
201:39–51. 1985.PubMed/NCBI
|
|
25
|
Rosen G: Preoperative (neoadjuvant)
chemotherapy for osteogenic sarcoma: A ten year experience.
Orthopedics. 8:659–664. 1985.PubMed/NCBI
|
|
26
|
Thiele OC, Freier K, Bacon C, Egerer G and
Hofele CM: Interdisciplinary combined treatment of craniofacial
osteosarcoma with neoadjuvant and adjuvant chemotherapy and
excision of the tumour: A retrospective study. Br J Oral Maxillofac
Surg. 46:533–536. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meyers PA, Heller G, Healey J, Huvos A,
Lane J, Marcove R, Applewhite A, Vlamis V and Rosen G: Chemotherapy
for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering
experience. J Clin Oncol. 10:5–15. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eilber FR and Rosen G: Adjuvant
chemotherapy for osteosarcoma. Semin Oncol. 16:312–322.
1989.PubMed/NCBI
|
|
29
|
Rosen G: Neoadjuvant chemotherapy for
osteogenic sarcoma: A model for the treatment of other highly
malignant neoplasms. Recent Results Cancer Res. 103:148–157. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Su W, Lai Z, Wu F, Lin Y, Mo Y, Yang Z and
Wu J: Clinical efficacy of preoperative chemotherapy with or
without ifosfamide in patients with osteosarcoma of the extremity:
Meta-analysis of randomized controlled trials. Med Oncol.
32:4812015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li S, Sun W, Wang H, Zuo D, Hua Y and Cai
Z: Research progress on the multidrug resistance mechanisms of
osteosarcoma chemotherapy and reversal. Tumor Biol. 36:1329–1338.
2015. View Article : Google Scholar
|
|
32
|
van Dalen EC, van der Pal HJ, Caron HN and
Kremer LC: Different dosage schedules for reducing cardiotoxicity
in cancer patients receiving anthracycline chemotherapy. Cochrane
Database Syst Rev: CD005008. 2006. View Article : Google Scholar
|
|
33
|
Liu Y, Xu Y, Lin N, Jiang S, Wang Y and Ye
Z: High-dose methotrexate (HD-MTX) used as an adjunct with other
chemotherapeutics for the treatment of osteosarcoma. Cell Biochem
Biophys. 71:1097–1104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Holmboe L, Andersen AM, Mørkrid L, Slørdal
L and Hall KS: High dose methotrexate chemotherapy:
Pharmacokinetics, folate and toxicity in osteosarcoma patients. Br
J Clin Pharmacol. 73:106–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang W, Zhang Q, Zheng TT, Zhen JC and
Niu XH: Delayed high-dose methotrexate excretion and influencing
factors in osteosarcoma patients. Chin Med J (Engl). 129:2530–2534.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kaneko T, Fujioka T, Suzuki Y, Sato Y and
Itoh H: Performance characteristics between TDx®FLx and
TBA™-25FR for the therapeutic drug monitoring of methotrexate. J
Pharm Health Care Sci. 2:72016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu W, Tang L, Lin F, Yao Y and Shen Z:
Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy
for stage IIB limb high-grade osteosarcoma: Does the analog matter?
Med Onco. 32:3072015. View Article : Google Scholar
|
|
38
|
Kobys VL, Konovalenko VF, Repinа NV,
Golovko TS, Gulak LO, Tarasova TO, Zaharycheva EV and Matyushok OF:
Treatment of large osteosarcoma in children: New approach. Exp
Oncol. 35:105–108. 2013.PubMed/NCBI
|
|
39
|
He F, Zhang W, Shen Y, Yu P, Bao Q, Wen J,
Hu C and Qiu S: Effects of resection margins on local recurrence of
osteosarcoma in extremity and pelvis: Systematic review and
meta-analysis. Int J Surg. 36:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu ZL, Wang G, Peng AF, Luo QF, Zhou Y
and Huang SH: Fatty acid synthase expression in osteosarcoma and
its correlation with pulmonary metastasis. Oncol Lett. 4:878–882.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sampson VB, Gorlick R, Kamara D and Kolb
Anders E: A review of targeted therapies evaluated by the pediatric
preclinical testing program for osteosarcoma. Front Oncol.
31:1322013.
|
|
42
|
Huang YJ, He AN, Sun YJ, Shen Z, Min DL
and Yao Y: Continuous-infusion ifosfamide and doxorubicin
combination as second-line chemotherapy for recurrent or refractory
osteosarcoma patients in China: A retrospective study. Asian Pac J
Cancer Prev. 16:2391–2395. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hattinger CM, Vella S, Tavanti E, Fanelli
M, Picci P and Serra M: Pharmacogenomics of second-line drugs used
for treatment of unresponsive or relapsed osteosarcoma patients.
Pharmacogenomics. 17:2097–2114. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Duffaud F, Egerer G, Ferrari S, Rassam H,
Boecker U and Bui-Nguyen B: A phase II trial of second-line
pemetrexed in adults with advanced/metastatic osteosarcoma. Eur J
Cancer. 48:564–570. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Heymann MF, Brown HK and Heymann D: Drugs
in early clinical development for the treatment of osteosarcoma.
Expert Opin Investig Drugs. 25:1265–1280. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lee JA, Paik EK, Seo J, Kim DH, Lim JS,
Yoo JY and Kim MS: Radiotherapy and gemcitabine-docetaxel
chemotherapy in children and adolescents with unresectable
recurrent or refractory osteosarcoma. Jpn J Clin Oncol. 46:138–143.
2016.PubMed/NCBI
|
|
48
|
Qi WX, He AN, Tang LN, Shen Z, Lin F and
Yao Y: Efficacy and safety of gemcitabine-docetaxel combination
therapy for recurrent or refractory high-grade osteosarcoma in
China: A retrospective study of 18 patients. Jpn J Clin Oncol.
42:427–431. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang DZ, Gao JF, Jing SF, Wei H, Huang XY
and Li CD: Antitumor effect of docetaxel in osteosarcoma by the
inhibition of Wnt signal channel. Drug Res (Stuttg). 65:597–601.
2015.PubMed/NCBI
|
|
50
|
Choi J, Ko E, Chung HK, Lee JH, Ju EJ, Lim
HK, Park I, Kim KS, Lee JH, Son WC, et al: Nanoparticulated
docetaxel exerts enhanced anticancer efficacy and overcomes
existing limitations of traditional drugs. Int J Nanomedicine.
10:6121–6132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
He A, Qi W, Huang Y, Sun Y, Shen Z, Zhao
H, Yang Y and Yao Y: Comparison of pirarubicin-based versus
gemcitabine-docetaxel chemotherapy for relapsed and refractory
osteosarcoma: A single institution experience. Int J Clin Oncol.
18:498–505. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xiao X, Wang W, Zhang H, Gao P, Fan B,
Huang C, Fu J, Chen G, Shi L, Zhu H, et al: Individualized
chemotherapy for osteosarcoma and identification of gene mutations
in osteosarcoma. Tumour Biol. 36:2427–2435. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Palmerini E, Jones RL, Marchesi E, Paioli
A, Cesari M, Longhi A, Meazza C, Coccoli L, Fagioli F, Asaftei S,
et al: Gemcitabine and docetaxel in relapsed and unresectable
high-grade osteosarcoma and spindle cell sarcoma of bone. BMC
Cancer. 16:2802016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zwerdling T, Krailo M, Monteleone P, Byrd
R, Sato J, Dunaway R, Seibel N, Chen Z, Strain J and Reaman G;
Children's Oncology Group, : Phase II investigation of docetaxel in
pediatric patients with recurrent solid tumors: A report from the
Children's Oncology Group. Cancer. 106:1821–1828. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Song BS, Seo J, Kim DH, Lim JS, Yoo JY and
Lee JA: Gemcitabine and docetaxel for the treatment of children and
adolescents with recurrent or refractory osteosarcoma: Korea cancer
center hospital experience. Pediatr Blood Cancer. 61:1376–1381.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lee JA, Jeon DG, Cho WH, Song WS, Yoon HS,
Park HJ, Park BK, Choi HS, Ahn HS, Lee JW, et al: Higher
gemcitabine dose was associated with better outcome of osteosarcoma
patients receiving gemcitabine-docetaxel chemotherapy. Pediatr
Blood Cancer. 63:1552–1556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Strippoli S, Traversa M, Cramarossa A,
Popescu O, Lorusso V and Guida M: Long-term response of gemcitabine
plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma:
A case report. Oncol Lett. 9:2567–2571. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yu WX, Tang LN, Lin F, Yao Y and Shen Z:
Comparison of pemetrexed plus cisplatin with gemcitabine plus
docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes
from a retrospective database monitored in a single institute.
Oncol Lett. 8:2243–2248. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mora J, Cruz CO, Parareda A and de Torres
C: Treatment of relapsed/refractory pediatric sarcomas with
gemcitabine and docetaxel. J Pediatr Hematol Oncol. 31:723–729.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
O'Day K and Gorlick R: Novel therapeutic
agents for osteosarcoma. Expert Rev Anticancer Ther. 9:511–523.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Grignani G, Palmerini E, Dileo P, Asaftei
SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F,
Casali PG, et al: A phase II trial of sorafenib in relapsed and
unresectable high-grade osteosarcoma after failure of standard
multimodal therapy: An Italian Sarcoma Group study. Ann Oncol.
23:508–516. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Grignani G, Palmerini E, Ferraresi V,
D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y,
Sangiolo D, Marchesi E, et al: Sorafenib and everolimus for
patients with unresectable high-grade osteosarcoma progressing
after standard treatment: A non-randomised phase 2 clinical trial.
Lancet Oncol. 16:98–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Magnan H, Goodbody CM, Riedel E, Pratilas
CA, Wexler LH and Chou AJ: Ifosfamide dose-intensification for
patients with metastatic Ewing sarcoma. Pediatr Blood Cancer.
62:594–597. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Liu L and Bhatoolaul N: Endostar as a
perioperative regimen with chemotherapy in osteosarcoma: A Review.
Biomed Lett. 2:60–65. 2016.
|
|
65
|
Hattinger CM, Tavanti E, Fanelli M, Vella
S, Picci P and Serra M: Pharmacogenomics of genes involved in
antifolate drug response and toxicity in osteosarcoma. Expert Opin
Drug Metab Toxicol. 13:245–257. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhu X, Du X, Deng X, Yi H, Cui S, Liu W,
Shen A and Cui Z: C6 ceramide sensitizes pemetrexed-induced
apoptosis and cytotoxicity in osteosarcoma cells. Biochem Biophys
Res Commun. 452:72–78. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Xu M, Xu CX, Bi WZ, Song ZG, Jia JP, Chai
W, Zhang LH and Wang Y: Effects of endostar combined multidrug
chemotherapy in osteosarcoma. Bone. 57:111–115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Venkatakrishnan K, Kramer WG, Synold TW,
Goodman DB, Sides E III and Oliva C: A pharmacokinetic,
pharmacodynamic, and electrocardiographic study of liposomal
mifamurtide (L-MTP-PE) in healthy adult volunteers. Eur J Clin
Pharmacol. 68:1347–1355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mori K, Ando K and Heymann D: Liposomal
muramyl tripeptide phosphatidyl ethanolamine: A safe and effective
agent against osteosarcoma pulmonary metastases. Expert Rev
Anticancer Ther. 8:151–159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Anderson PM, Wiseman GA, Dispenzieri A,
Arndt CA, Hartmann LC, Smithson WA, Mullan BP and Bruland OS:
High-dose samarium-153 ethylene diamine tetramethylene phosphonate:
Low toxicity of skeletal irradiation in patients with osteosarcoma
and bone metastases. J Clin Oncol. 20:189–196. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Lin F, Zheng SE, Shen Z, Tang LN, Chen P,
Sun YJ, Zhao H and Yao Y: Relationships between levels of CXCR4 and
VEGF and blood-borne metastasis and survival in patients with
osteosarcoma. Med Oncol. 28:649–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Qu L and Liu B: Cyclooxygeanse-2 promotes
metastasis in osteosarcoma. Cancer Cell Int. 15:692015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kleinerman ES: Current advances in
osteosarcoma. Springer International Publishing Switzerland.
35:5942014.
|
|
74
|
Endo-Munoz L, Evdokiou A and Saunders NA:
The role of osteoclasts and tumour-associated macrophages in
osteosarcoma metastasis. Biochim Biophys Acta. 1826:434–442.
2012.PubMed/NCBI
|
|
75
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Geller DS and Gorlick R: Osteosarcoma: A
review of diagnosis, management, and treatment strategies. Clin Adv
Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
|
|
77
|
Chou AJ, Geller DS and Gorlick R: Therapy
for osteosarcoma: Where do we go from here? Paediatr Drugs.
10:315–327. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
van Oosterwijk JG, Anninga JK, Gelderblom
H, Cleton-Jansen AM and Bovée JV: Update on targets and novel
treatment options for high-grade osteosarcoma and chondrosarcoma.
Hematol Oncol Clin North Am. 27:1021–1048. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Savage SA and Mirabello L: Using
epidemiology and genomics to understand osteosarcoma etiology.
Sarcoma. 2011:5481512011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
ESMO/European Sarcoma Network Working
Group: Bone sarcomas: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 25 Suppl
3:iii113–iii123. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wang J and Li G: Mechanisms of
methotrexate resistance in osteosarcoma cell lines and strategies
for overcoming this resistance. Oncol Lett. 9:940–944. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Miller BJ, Cram P, Lynch CF and Buckwalter
JA: Risk factors for metastatic disease at presentation with
osteosarcoma: An analysis of the SEER database. J Bone Joint Surg
Am. 95:e892013. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Botter SM, Neri D and Fuchs B: Recent
advances in osteosarcoma. Curr Opin Pharmacol. 16:15–23. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Rapkin L, Qayed M, Brill P, Martin M,
Clark D, George BA, Olson TA, Wasilewski-Masker K, Alazraki A and
Katzenstein HM: Gemcitabine and docetaxel (GEMDOX) for the
treatment of relapsed and refractory pediatric sarcomas. Pediatr
Blood Cancer. 59:854–858. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Gosiengfiao Y, Reichek J, Woodman J,
Ben-Ami T and Walterhouse D: Gemcitabine with or without docetaxel
and resection for recurrent osteosarcoma: The experience at
children's memorial hospital. J Pediatr Hematol Oncol. 34:e63–e65.
2012. View Article : Google Scholar : PubMed/NCBI
|
